Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (4977)	7/18/1998 10:40:00 AM
From: Brander	Respond to of 7041

" The patent office does not make any determination as to the efficacy of drugs - that's the job of the FDA." Correct. If the FDA does approve Vasomax, this patent appears to protective of any fast acting (disintgrates in less than 20 minutes) oral form of phentolamine. I don't know much about patent law, but if the FDA approves Vasomax, and if the patent is enforceable, it seems very broad and protective over anyone else making a fast acting oral form of phentolamine. You are correct about the mesylate and HCl. I mistakenly said sulfate.